Unknown

Dataset Information

0

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.


ABSTRACT: Current T-cell engineering approaches redirect patient T cells to tumors by transducing them with antigen-specific T-cell receptors (TCRs) or chimeric antigen receptors (CARs) that target a single antigen. However, few truly tumor-specific antigens have been identified, and healthy tissues that express the targeted antigen may undergo T cell-mediated damage. Here we present a strategy to render T cells specific for a tumor in the absence of a truly tumor-restricted antigen. T cells are transduced with both a CAR that provides suboptimal activation upon binding of one antigen and a chimeric costimulatory receptor (CCR) that recognizes a second antigen. Using the prostate tumor antigens PSMA and PSCA, we show that co-transduced T cells destroy tumors that express both antigens but do not affect tumors expressing either antigen alone. This 'tumor-sensing' strategy may help broaden the applicability and avoid some of the side effects of targeted T-cell therapies.

SUBMITTER: Kloss CC 

PROVIDER: S-EPMC5505184 | BioStudies | 2013-01-01

REPOSITORIES: biostudies

Similar Datasets

2018-01-01 | S-EPMC5749625 | BioStudies
2017-01-01 | S-EPMC5384358 | BioStudies
1000-01-01 | S-EPMC3899402 | BioStudies
1000-01-01 | S-EPMC5363304 | BioStudies
2014-01-01 | S-EPMC4108460 | BioStudies
2020-01-01 | S-EPMC7441178 | BioStudies
1000-01-01 | S-EPMC5895166 | BioStudies
1000-01-01 | S-EPMC5835118 | BioStudies
2020-01-01 | S-EPMC7183102 | BioStudies
2009-01-01 | S-EPMC2891877 | BioStudies